论文部分内容阅读
目的:探讨不同干扰素(聚乙二醇干扰素和普通干扰素a-1b)在慢性丙型肝炎基因(CHC)2a型患者中的疗效与复发情况。方法:收集2012年7月—2014年7月青海省第四人民医院基因分型2a型初治患者的70例,随机分为采用聚乙二醇干扰素组(A组)和普通干扰素a-1b组(B组)各35例,观察应答率和停药复发情况。结果:两组患者在经过48周的治疗后,聚乙二醇干扰素25例患者获得早期病毒学应答(EVR),30例患者获得持续病毒学应答(SVR),3例患者无应答(NR),5例患者复发。普通干扰素a-1b组21例患者获得早期病毒学应答(SVR),28例患者获得持续病毒学应答,6例患者无应答,8例患者复发。停药后复发率无明显差异。白细胞计数下降和血小板减少的发生率聚乙二醇干扰素高于普通干扰素a-1b,差异有统计学意义。结论:两组EVR、治疗结束时病毒学应答(ETVR)差异无统计学意义,普通干扰素联合利巴韦林取得较好的疗效,且不良反应减少,患者耐受性好,复发率低。
Objective: To investigate the efficacy and recurrence of different interferon (peginterferon and common interferon a-1b) in patients with chronic hepatitis C (CHC) type 2a. Methods: Seventy patients with genotype 2a primary treatment in Qinghai Fourth People’s Hospital from July 2012 to July 2014 were randomly divided into two groups: pegylated interferon group (group A) and ordinary interferon -1b group (B group) of 35 cases, observe the response rate and the withdrawal of relapse. Results: After 48 weeks of treatment, 25 patients with peginterferonie acquired early virological response (EVR), 30 patients achieved sustained virological response (SVR), and 3 patients had no response (NR ), 5 patients relapsed. Early viral response (SVR) was obtained in 21 patients in the usual interferon a-1b group, in 28 patients with a sustained virological response, in 6 patients with no response, and in 8 patients relapsed. There was no significant difference in relapse rate after stopping drug treatment. The incidence of leukopenia and thrombocytopenia was higher in peginterferon alfa-1b than in normal interferon alfa-1b, the difference was statistically significant. Conclusion: There was no significant difference between the two groups in EVR and ETVR at the end of treatment. The common interferon combined with ribavirin achieved better curative effect, less adverse reactions, better patient tolerance and lower recurrence rate.